WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010141427) TREATMENT OF OPHTHALMOLOGIC DISORDERS MEDIATED BY ALBHA-CARBONIC ANHYDRASE ISOFORMS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/141427    International Application No.:    PCT/US2010/036836
Publication Date: 09.12.2010 International Filing Date: 01.06.2010
IPC:
A61K 31/506 (2006.01), A61K 45/06 (2006.01), A61P 27/00 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35 CH-4056 Basel (CH) (For All Designated States Except US).
UNIVERSITY OF TAMPERE [FI/FI]; Kalevantie 2 FI-33014 Tampere (FI) (For All Designated States Except US).
SUPURAN, Claudiu [IT/IT]; (IT) (For US Only).
DRYJA, Thaddeus [US/US]; (US) (For US Only).
BRIGELL, Mitchell [US/US]; (US) (For US Only).
PARKKILA, Seppo [FI/FI]; (FI) (For US Only)
Inventors: SUPURAN, Claudiu; (IT).
DRYJA, Thaddeus; (US).
BRIGELL, Mitchell; (US).
PARKKILA, Seppo; (FI)
Agent: WOODS, Daniel; Novartis Patent Department One Health Plaza Bldg. 101 East Hanover, NJ 07936 (US)
Priority Data:
09161720.9 02.06.2009 EP
61/185,328 09.06.2009 US
Title (EN) TREATMENT OF OPHTHALMOLOGIC DISORDERS MEDIATED BY ALBHA-CARBONIC ANHYDRASE ISOFORMS
(FR) TRAITEMENT DE TROUBLES OPHTALMOLOGIQUES À MÉDIATION PAR DES ISOFORMES DE L'ANHYDRASE CARBONIQUE ALPHA
Abstract: front page image
(EN)The present invention pertains to 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof, or 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[5-(4-methyl-1 H-imidazol-1-yl)-3-(trifluoro- methyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof, for the treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms.
(FR)La présente invention porte sur le 4-(4-méthylpipérazin-1-ylméthyl)-N-[4-méthyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phényl]-benzamide ou un sel pharmaceutiquement acceptable de celui-ci, ou le 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[5-(4-méthyl-1H-imidazol-1-yl)-3-(trifluoro-méthyl)phényl]benzamide ou un sel pharmaceutiquement acceptable de celui-ci, pour le traitement de troubles ophtalmologiques à médiation par des isoformes de l'anhydrase carbonique alpha.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)